Arkolith/Insider Trading/MIRM/Form 4

Ramasastry Saira

DirectorMirum Pharmaceuticals, Inc. (MIRM) · full profile →Form 4 · filed Mar 17, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$182K
Net Open-Market Flow
-$182K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 16, 2026Option exercise(M)2K$23.51$47K2K
Mar 16, 2026Sell(S)2K$90.76$182K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 16, 2026Option exercise(M)2K—$04K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001547959-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML